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Seasonal vaccination campaigns for influenza in developed and developing countries create a massive demand 
for 500 million (2015) vaccine doses every year [1]. Besides egg-based vaccine manufacturing, production 
platforms based on animal cell culture increasingly contribute to this overall growing market. In order to intensify 
cell culture-based influenza virus production, high-cell-density (HCD) cultivation of suspension cells can be 
applied to improve virus titer, process productivity and production costs [2]. For process optimization and 
evaluation of HCD conditions, cells cultivated using semi-perfusion approaches in small shakers can be used as 
a scale-down model for bioreactors operating in full perfusion mode [3]. 
 
In this study, a previously developed MDCK suspension cell line [4] was adapted to a new serum free 
medium [5] to facilitate higher growth rate, cell density and virus titer both in batch and in HCD. Therefore, 
MDCK cells cultivated in Smif-8 medium were slowly adapted to a new cultivation medium (Xeno™) by stepwise 
increasing the Xeno content. Fully adapted cells were cultivated in shaker flasks to evaluate the performance of 
influenza A virus production in batch and HCD. Cell densities exceeding 2∙107 cells/mL were achieved in 
shakers using semi-perfusion, where cell free medium was manually replaced with fresh medium. Volume and 
time interval of media replacement were chosen to achieve a constant cell-specific perfusion rate of 
2.5 pL/(cell h). Cell cultures were infected with influenza virus (A/PR/8/34 H1N1 RKI) with trypsin addition. Cell 
count, viability, main metabolites and virus titer (HA-assay & TCID50) were monitored pre and post infection. 
 
Medium adaptation resulted in a MDCK suspension cell line with morphological, growth, and metabolic 
characteristics different from parental cells. Cells fully adapted to Xeno medium were growing to higher cell 
densities (1.4∙107 vs 6∙106 cells/mL) with higher specific growth rate (µmax: 0.036 vs 0.026 1/h), cells were bigger 
(15-16 vs 13-14 µm) and grew without aggregate formation. Due to higher cell densities at time of infection, 
virus titers up to 3.6 log10(HAU/100µL) were reached. In semi-perfusion, adapted MDCK cells were grown up to 
6∙107 cells/mL, however, maximum virus titer and productivity were observed with 4∙107 cells/mL. In multiple 
harvests, very high virus titer exceeding 4 log10(HAU/100µL) and up to 9∙109 virions/mL (TCID50) were 
measured, which corresponded to an accumulated titer of 4.5 log10(HAU/100µL). Cell-specific virus titer was 
similar or higher compared to the reference batch infections, depending on perfusion and infection strategy.  
 
Overall, results in this semi-perfusion scale-down model for influenza A virus production suggest a highly 
efficient and productive upstream process for influenza virus production, with an up to six-fold improved space 
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